Invasive Bladder Cancer Clinical Trials

1 recruiting

Invasive Bladder Cancer Trials at a Glance

26 actively recruiting trials for invasive bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Austin, Shanghai, and Los Angeles. Lead sponsors running invasive bladder cancer studies include The First Affiliated Hospital with Nanjing Medical University, Ferring Pharmaceuticals, and Assiut University.

Browse invasive bladder cancer trials by phase

Treatments under study

About Invasive Bladder Cancer Clinical Trials

Looking for clinical trials for Invasive Bladder Cancer? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Invasive Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Invasive Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled66 locationsNCT06545955
Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

Breast CancerLiver CancerPancreatic Cancer+9 more
Natera, Inc.9,600 enrolled1 locationNCT07318051
Recruiting
Not Applicable

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

Muscle-Invasive Bladder CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)
University of Aarhus30 enrolled1 locationNCT07339761
Recruiting
Phase 2

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Not Applicable

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Bladder CancerMuscle Invasive Bladder Cancer (MIBC)Muscle Invasive Bladder Cancer Urothelial Carcinoma+1 more
Johns Hopkins University130 enrolled2 locationsNCT07225205
Recruiting
Phase 2

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1Phase 2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Not Applicable

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Muscle Invasive Bladder Cancer
Assiut University76 enrolled2 locationsNCT07202819
Recruiting
Phase 1

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Ractigen Therapeutics.72 enrolled3 locationsNCT06351904
Recruiting
Phase 3

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

Bladder CarcinomaBladder NeoplasmMuscle Invasive Bladder Cancer (MIBC)+2 more
University of Rome Tor Vergata92 enrolled1 locationNCT07067749
Recruiting
Phase 2

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Nonmuscle-invasive Bladder Cancer
ImmVira Pharma Co. Ltd160 enrolled2 locationsNCT06971614
Recruiting
Not Applicable

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT07036731
Recruiting
Phase 2Phase 3

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Muscular Invasive Bladder Cancer (MIBC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.840 enrolled1 locationNCT06879145
Recruiting
Phase 2

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137
Recruiting
Phase 1

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Muscle Invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University10 enrolled1 locationNCT06916494
Recruiting
Phase 3

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang180 enrolled3 locationsNCT06696794